World Library  
Flag as Inappropriate
Email this Article

Ocular ischemic syndrome

Article Id: WHEBN0007596876
Reproduction Date:

Title: Ocular ischemic syndrome  
Author: World Heritage Encyclopedia
Language: English
Subject: Central retinal vein occlusion, Amaurosis fugax, OIS, Recent additions 96, Transient ischemic attack
Collection: Disorders of Choroid and Retina
Publisher: World Heritage Encyclopedia

Ocular ischemic syndrome

Ocular ischemic syndrome
Classification and external resources
ICD-10 H34
DiseasesDB 34069
eMedicine oph/487

Ocular ischemic syndrome is the constellation of ocular signs and symptoms secondary to severe, chronic arterial hypoperfusion to the eye.[1] Amaurosis fugax is a form of acute vision loss caused by reduced blood flow to the eye that may be a warning sign of an impending stroke. Consequently, those with transient blurring of vision are advised to urgently seek medical attention for a thorough evaluation of the carotid artery. Anterior segment ischemic syndrome is a similar ischemic condition of anterior segment usually seen in post-surgical cases. Retinal arterial occlusion leads to rapid death of retinal cells, thereby resulting in severe loss of vision.


  • Symptoms and signs 1
  • Causes 2
  • Complications 3
  • Treatment and management 4
  • Differential diagnoses 5
  • References 6

Symptoms and signs

Those with ocular ischemic syndrome are typically between the ages of 50 and 80 (patients over 65) ;[2][3] twice as many men as women are affected.[3] More than 90% of those presenting with the condition have vision loss.[1] Patients may report a dull, radiating ache over the eye and eyebrow.[1] Those with ocular ischemic syndrome may also present with a history of other systemic diseases including arterial hypertension, diabetes mellitus, coronary artery disease, previous stroke, and hemodialysis.[4][5]

The condition presents with visual loss secondary to hypoperfusion of the eye structures. The patient presents with intractable pain or ocular angina. On dilated examination, there may be blot retinal hemorrhages along with dilated and beaded retinal veins. The ocular perfusion pressure is decreased. The corneal layers show edema and striae. There is mild anterior uveitis. A cherry-red spot in macula may be seen, along with cotton-wool spots elsewhere, due to retinal nerve fiber layer hemorrhages. The retinal arteries may show spontaneous pulsations.


Severe ipsilateral or bilateral carotid artery stenosis or occlusion is the most common cause of ocular ischemic syndrome.[1] The syndrome has been associated with occlusion of the common carotid artery, internal carotid artery, and less frequently the external carotid artery.[6] Other causes include:


If carotid occlusive disease results in ophthalmic artery occlusion, general ocular ischemia may result in retinal neovascularization, rubeosis iridis, cells and flare, iris necrosis, and cataract. The condition leads to neovascularization in various eye tissues due to the ischemia. The eye pressure may become high due to associated neovascular glaucoma. An ischemic optic neuropathy may eventually occur.

Treatment and management

Quick determination of the cause may lead to urgent measures to save the eye and life of the patient. High clinical suspicion should be kept for painless vision loss in patients with atherosclerosis, deep venous thrombosis, atrial fibrillation, pulmonary thromboembolism or other previous embolic episodes. Those caused by a carotid artery embolism or occlusion have the potential for further stroke by detachment of embolus and migration to an end-artery of the brain.[9] Hence, proper steps to prevent such an eventuality need to be taken.

Retinal arterial occlusion is an ophthalmic emergency, and prompt treatment is essential. Completely anoxic retina in animal models causes irreversible damage in about 90 minutes. Nonspecific methods to increase blood flow and dislodge emboli include digital massage, 500 mg IV acetazolamide and 100 mg IV methylprednisolone (for possible arteritis). Additional measures include paracentesis of aqueous humor to decrease IOP acutely. An ESR should be drawn to detect possible giant cell arteritis. Improvement can be determined by visual acuity, visual field testing, and by ophthalmoscopic examination.

At a later stage, pan-retinal photocoagulation (PRP) with an argon laser appears effective in reducing the neovascular components and their sequelae.

The visual prognosis for ocular ischemic syndrome varies from usually poor to fair, depending on speed and effectiveness of the intervention. However, prompt diagnosis is crucial as the condition may be a presenting sign of serious cerebrovascular and ischemic heart diseases.[5]

In 2009, the Undersea and Hyperbaric Medical Society added "central retinal artery occlusion" to their list of approved indications for hyperbaric oxygen (HBO).[10][11] When used as an adjunctive therapy, the edema reducing properties of HBO, along with down regulation of inflammatory cytokines may contribute to the improvement in vision.[12] Prevention of vision loss requires that certain conditions be met: the treatment be started before irreversible damage has occurred (over 24 hours), the occlusion must not also occur at the ophthalmic artery, and treatment must continue until the inner layers of the retina are again oxygenated by the retinal arteries.[13]

Differential diagnoses

  • Central retinal vein occlusion
  • Diabetic retinopathy: The presence of retinal hemorrhages, particularly in those who have diabetes, may also be caused by diabetic retinopathy.[14] Given the bilateral nature of diabetic retinopathy, however, one should suspect ocular ischemic syndrome when retinal ischemia is unilateral.[15]


  1. ^ a b c d De Graeve C, Van de Sompel W, Claes C. "Ocular ischemic syndrome: two case reports of bilateral involvement." Bull Soc Belge Ophtalmol. 1999;273:69-74. PMID 10546383.
  2. ^ Friedberg MA, Rapuano CJ. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, J.B. Lippincott, 1994.
  3. ^ a b "Ocular Ischemic Syndrome." Accessed October 25, 2006.
  4. ^ Chen KJ, Chen SN, Kao LY, Ho CL, Chen TL, Lai CC, Wu SC. (August 2001). "Ocular ischemic syndrome". Chang Gung Medical Journal 24 (8): 483–91.  
  5. ^ a b Mizener JB, Podhajsky P, Hayreh SS (May 1997). "Ocular ischemic syndrome". Ophthalmology 104 (5): 859–64.  
  6. ^ Alizai AM, Trobe JD, Thompson BG, Izer JD, Cornblath WT, Deveikis JP (December 2005). "Ocular ischemic syndrome after occlusion of both external carotid arteries". Journal of Neuro-Ophthalmology 25 (4): 268–72.  
  7. ^ Koz OG, Ates A, Numan Alp M, Gultan E, Karaaslan Y, Kural G (January 2007). "Bilateral ocular ischemic syndrome as an initial manifestation of Takayasu's arteritis associated with carotid steal syndrome". Rheumatology International 27 (3): 299–302.  
  8. ^ Hamed LM, Guy JR, Moster ML, Bosley T (June 1992). "Giant cell arteritis in the ocular ischemic syndrome". American Journal of Ophthalmology 113 (6): 702–5.  
  9. ^ Kaiboriboon K, Piriyawat P, Selhorst JB (May 2001). "Light-induced amaurosis fugax". American Journal of Ophthalmology 131 (5): 674–6.  
  10. ^ The Undersea and Hyperbaric Medical Society (UHMS), Hyperbaric Oxygen Therapy Committee. Guidelines: Indications for Hyperbaric Oxygen. Durham, NC: UHMS; 2009.
  11. ^ Butler FK, Hagan C, Murphy-Lavoie H (2008). "Hyperbaric oxygen therapy and the eye". Undersea & Hyperbaric Medicine : Journal of the Undersea and Hyperbaric Medical Society, Inc 35 (5): 333–87.  
  12. ^ Wright JK, Franklin B, Zant E (2007). "Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen". Undersea and Hyperbaric Medicine 34 (5): 315–9.  
  13. ^ Butler Jr, FK (2010). "Hyperbaric oxygen for central retinal artery occlusion". Wound Care & Hyperbaric Medicine 1 (3): 25. 
  14. ^ Munch IC, Larsen M (Aug 2005). "[The ocular ischemic syndrome.]". Ugeskr Laeger 167 (35): 3269–73.  
  15. ^ Bigou MA, Bettembourg O, Hebert T, Cochener B (Jan 2006). "[Unilateral ocular ischemic syndrome in a diabetic patient.]". J Fr Ophtalmol 29 (1): e2.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.